News for Castle Biosciences Inc Stock (CSTL)

New Study Shows that the Drug-Drug Interactions and Lifestyle Factors Provided by Castle Biosciences' IDgenetix® Test Significantly Improve Medication Recommendations Over Drug-Gene Interactions Alone for Patients 65 and Older

Business Wire • 03/15/24

Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum

Business Wire • 03/12/24

Castle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual Meeting

Business Wire • 03/08/24

In Novel Cohort, New Data Confirms DecisionDx®-SCC Provides Significant, Independent and Clinically Actionable Risk-Stratification of Patients, Including in Various High-Risk Subgroups

Business Wire • 03/07/24

Castle Biosciences, Inc. (CSTL) Q4 2023 Earnings Call Transcript

Seeking Alpha • 02/29/24

Castle Biosciences, Inc. (CSTL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks Investment Research • 02/29/24

Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Tops Revenue Estimates

Zacks Investment Research • 02/28/24

Castle Biosciences Reports Fourth Quarter and Full-Year 2023 Results

Business Wire • 02/28/24

Insights Into Castle Biosciences, Inc. (CSTL) Q4: Wall Street Projections for Key Metrics

Zacks Investment Research • 02/26/24

Study Finds DecisionDx®-Melanoma Significantly Improves the Risk Stratification of Patients with Stage I Melanoma Compared to American Joint Committee on Cancer 8th Edition Staging

Business Wire • 02/26/24

Castle Biosciences to Release Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call on Wednesday, Feb. 28, 2024

Business Wire • 02/07/24

New Study Highlights Significant Potential Medicare Savings Through Use of Castle Biosciences' DecisionDx®-SCC Test to Guide Adjuvant Radiation Therapy Decisions in Patients with Cutaneous Squamous Cell Carcinoma

Business Wire • 01/18/24

Castle Biosciences Presents Data Supporting the Utility of Its Tests in the Clinical Care of Patients with Skin Cancers at the 2024 Winter Clinical Dermatology Conference - Hawaii®

Business Wire • 01/14/24

Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2023 Results

Business Wire • 01/08/24

How Much Upside is Left in Castle Biosciences, Inc. (CSTL)? Wall Street Analysts Think 67.01%

Zacks Investment Research • 12/12/23

Study Finds Nurse Practitioners and Physician Assistants Would Alter Patient Care Decisions Based on DecisionDx®-Melanoma Test Results

Business Wire • 12/01/23

Castle Biosciences Announces Multiple Data Presentations at the 2023 American Society for Dermatologic Surgery Annual Meeting

Business Wire • 11/14/23

Castle Biosciences Ranked Among the Top Workplaces in Houston by the Houston Chronicle for the Third Consecutive Year

Business Wire • 11/13/23

Real-World Evidence Confirms IDgenetix®-Guided Medication Management Significantly Improves Response and Remission Rates in Patients with Major Depressive Disorder

Business Wire • 11/08/23

Castle Biosciences to Present at Upcoming Investor Conferences

Business Wire • 11/08/23

Castle Biosciences, Inc. (CSTL) Q3 2023 Earnings Call Transcript

Seeking Alpha • 11/03/23

Castle Announces Early Exploratory Study Data for Potential Development of a Complementary Test to Accompany DecisionDx®-UM That Could Aid in the Early Detection of Uveal Melanomas

Business Wire • 11/03/23

Here's What Key Metrics Tell Us About Castle Biosciences, Inc. (CSTL) Q3 Earnings

Zacks Investment Research • 11/03/23

Early Discovery Data Shows Ability of Castle Biosciences' Pipeline Program to Distinguish Between Responders and Non-Responders to an Atopic Dermatitis Therapy

Business Wire • 11/02/23

Castle Biosciences Reports Third Quarter 2023 Results

Business Wire • 11/02/23